

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
July 25, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): July 19, 2013**

**LA JOLLA PHARMACEUTICAL COMPANY**

**(Exact name of registrant as specified in its charter)**

**California**  
**(State or other jurisdiction**  
  
**of incorporation or organization)**

**0-24274**  
**(Commission**  
  
**File Number)**

**33-0361285**  
**(I.R.S. Employer**  
  
**Identification No.)**

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

**4660 La Jolla Village Drive, Suite 1070, San Diego, California 92122**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (858) 207-4264**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 2.02 Results of Operations and Financial Condition.**

On July 19, 2013, La Jolla Pharmaceutical Company (the Company ) reported its results of operations for the quarter ended June 30, 2013. A copy of the release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the Report ). The press release should be read in conjunction with the note regarding forward looking statements, which is included in the text of the release.

*The information in this Item 2.02 and attached Exhibit 99.1 to this Report will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.*

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(d) *Exhibits.* The following exhibit is filed with this report on Form 8-K:

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated July 19, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: July 25, 2013

By: /s/ George F. Tidmarsh  
Name: George F. Tidmarsh, M.D. Ph.D.  
Title: President and Chief Executive Officer